Merit Medical Systems, Inc. (MMSI) Q3 2026 earnings review
Merit Medical underlying sales grow 9%, while inventory ties up cash
Merit Medical Systems, a maker of disposable surgical catheters and specialty hospital devices, grew underlying sales near 9% while keeping overhead costs flat. Reported revenue rose 8% to $416 million, and profit per share excluding one-offs climbed 22% to $1.12, beating what the company's own plan pointed to. Chief executive Martha G. Aronson raised the full-year profit outlook by $0.05 at the middle of the range, though by our math the plan leaves fourth-quarter profit growth slowing to 6%.
| Sales from businesses owned a year ago (constant currency) | +8.9% above 7.0–8.0% plan |
|---|---|
| Reported revenue | $416.2M +8.4% from a year ago |
| Profit per share, excluding one-offs | $1.12 +21.7% from a year ago |
| Full-year profit outlook | Raised $0.05 middle of the range: $4.35 (+14%) |
⚖️ Verdict: 🟢 Bullish
The story got better because the rebound in component sales to other device makers held at 15% for a second straight quarter, proving it was not a one-time restocking bump. Specialized therapeutic tools also grew 14%, lifting their share of sales to 34%. One caution: acquired revenue missed the company's third-quarter plan during the launch of View Point's cancer-detection system, and rising inventory kept nine-month free cash flow down 9%.
The question now is whether Merit's recent acquisitions and working-capital discipline can match the strength of its existing product lines. Either View Point sales speed up and inventory drops to reach the $200 million cash flow target, or deal dilution and warehouse stockpiles drag on returns. Fourth-quarter cash flow and the 2027 strategic plan will settle it.
🐂 Bull Case
OEM Sales Grew 15% for a Second Quarter
Merit sells medical components to other device makers through its original equipment manufacturer (OEM) units. After those customers worked down their own warehouse stockpiles late last year and early this year, OEM sales jumped 15.5% in the second quarter. Management noted at the time that some of that rebound came from delayed contract transfers, leaving open whether underlying demand had truly recovered.
In the third quarter, combined OEM sales across the Foundational and Therapeutic categories grew 15.4% from a year ago to $59.4 million, by our math. Foundational OEM rose 11.5% to $46.3 million, while Therapeutic OEM climbed 31.5% to $13.1 million. Furthermore, other long-term obligations on the balance sheet—which carry advance payments from OEM customer contracts—rose to $43.4 million from $10.3 million at year-end.
Two straight quarters of 15% growth show that customer ordering has recovered beyond a one-time restocking bump. Because the fourth quarter of last year was when OEM sales fell 15%, Merit now enters the easiest comparison of the year with a growing order book.
What to watch: combined OEM revenue growth in the fourth quarter. A third consecutive double-digit gain would confirm that customer inventory cuts are fully behind the business.
Therapeutic Devices Keep Outgrowing the Core
Beginning this year, Merit split its product line into Foundational devices—everyday hospital supplies like catheters, inflation devices and custom trays—and Therapeutic devices, which are specialized tools used to treat heart, cancer and digestive conditions. Chief executive Martha G. Aronson highlighted "better-than-expected demand for Merit’s products across both our Foundational and our Therapeutic platforms" during the third quarter.
- Total Therapeutic sales: $140.5 million, up 14.0% from a year ago (33.8% of total revenue by our math)
- Endoscopy (digestive tract tools): $23.4 million, up 32.9%, helped by the C2 CryoBalloon acquisition
- Oncology (cancer treatment tools): $27.1 million, up 16.4%
- Total Foundational sales: $275.7 million, up 5.7%, dragged down by a 15.9% drop in Procedural Solutions
Therapeutic products grew more than twice as fast as Foundational supplies, lifting their share of Merit's revenue by 1.7 percentage points from a year ago, by our math. That shift keeps total underlying sales growing near 9% even as custom procedural trays shrink.
What to watch: Therapeutic revenue share in the fourth quarter. Passing 34% of total sales would keep overall growth above the company's 5% to 7% three-year target range.
Flat Overhead Costs Lifted the Operating Margin
Merit's three-year financial plan, called the Continued Growth Initiative, targets an operating margin excluding one-offs between 20% and 22% by the end of 2026. Previously, manufacturing transfers to Mexico and freight savings drove gross margin higher to do the heavy lifting. This quarter, gross margin went the other way, falling 0.3 percentage points on a reported basis to 48.2%, and 0.8 points excluding one-offs to 52.8%, as cost of sales rose to 51.8% of revenue.
Even with lower gross margin, operating margin excluding one-offs rose 1.6 percentage points from a year ago to 21.3%, and reported operating margin jumped 3.0 points to 14.1%. The gain came from overhead and research spending: selling and administrative expenses fell 2.5 percentage points of revenue to 28.7%, and research and development fell 0.9 points to 5.4%, by our math, because both lines shrank slightly in dollar terms while sales grew 8.4%.
What to watch: gross margin excluding one-offs in the fourth quarter. A rebound above 53% would show whether the third-quarter dip was temporary mix or tariff pressure.
🐻 Bear Case
Acquired Sales Missed the Plan in Launch Quarter
Aronson said third-quarter results "exceeded the high end of our expectations" on strong product demand. However, Merit's own reconciliation table shows that revenue from recent acquisitions excluded from underlying growth—covering the C2 CryoBalloon device bought in November 2025 and View Point Medical bought in April 2026—totaled $2.63 million in the quarter.
On last quarter's call, finance chief Raul Parra forecast $2.8 million to $3.8 million of acquisition revenue for the third quarter, timed with the July US commercial launch of View Point's OneMark tissue-detection system. Landing at $2.63 million missed the bottom of that range by 6%, by our math. Because C2 CryoBalloon was already generating over $2 million a quarter in the first half, the figures indicate that OneMark recorded minimal initial sales.
This matters because Merit paid $90 million in cash up front for View Point, carries $50 million in potential milestone payments, and forecast $2 million to $4 million of 2026 sales stepping up to $14 million to $16 million in 2027.
What to watch: fourth-quarter acquisition revenue in the reconciliation table. A reading below $3.5 million would leave View Point short of its first-year sales target.
Rising Inventory Holds Back Cash Flow
Merit has targeted at least $200 million of free cash flow for 2026, and management previously said that first-half inventory builds for product transfers and new launches would taper off in the second half. Instead, balance-sheet inventories rose another $16.9 million in the third quarter to $391.0 million—up $57.3 million since December and up 19.7% from a year ago, by our math, more than double the 8.4% pace of sales.
Working capital tied up $78.9 million of cash over the first nine months, compared with $31.6 million in the prior-year period. As a result, nine-month operating cash flow fell 11.9% to $175.2 million, and free cash flow declined 8.5% to $129.5 million even after Merit cut capital spending by $11.6 million. In the third quarter alone, free cash flow was $53.0 million against $52.6 million a year ago.
What to watch: fourth-quarter free cash flow, which must reach $70.5 million by our math to hit the $200 million annual floor, requiring inventory balances to finally come down.
Risks this quarter didn't answer
Several standing concerns from prior quarters received no new figures in the third-quarter earnings release or presentation.
- Profitability by product category: still undisclosed under the single-segment structure, leaving the margin benefit of faster Therapeutic growth unverifiable.
- Post-2026 financial targets: Aronson said the team is "finalizing our longer-term strategic plan", so investors still wait until early 2027 for three-year targets and any product-line exits.
- Tariff costs and refunds: no update in the release on the $16 million full-year tariff assumption or the $1.5 million in refunds held by a freight forwarder.
- WRAPSODY stent sales: no quarterly figure disclosed against the $7 million full-year US target.
- Share buybacks: zero shares repurchased in the first nine months despite cash rising to $503.6 million, as management spent $45 million on Solo Pace instead.
👓 Other Themes
Merit Spends $45 Million on Heart-Valve Pacing
On October 13, Merit paid approximately $45 million to buy the remaining 82% of Solo Pace, a maker of temporary heart-pacing systems "exclusively engineered for transcatheter aortic valve replacement (TAVR) and other transcatheter heart valve (THV) procedures". Merit already distributed the devices and wants "to expand its structural heart portfolio, with a focus on technologies designed to simplify procedural workflows". The deal will not move 2026 results and will slightly lift 2027 profit per share excluding one-offs, despite $1.5 million in lost interest income and $3.2 million in transaction costs.
💲 Other KPIs
US sales rose 11.0% from a year ago (11.2% in constant currency), speeding up from 9.4% across the first nine months. International sales grew 4.4% (3.3% in constant currency), slowing from their 7.0% nine-month pace. Domestic hospitals accounted for 61.5% of total company revenue in the quarter, by our math.
Cash and cash equivalents climbed by $57.1 million over the first nine months to $503.6 million, even after paying $93.0 million for acquisitions and receiving $25.6 million from selling DualCap. Total debt stayed at $747.5 million, leaving net debt at $243.9 million by our math before October's $45 million Solo Pace purchase.
Weighted average diluted shares rose 0.8% from a year ago and 0.6% from last quarter. The full-year outlook now includes about $0.01 per share of dilution from Merit's 2029 convertible notes, down from $0.03 in the prior outlook.
🔮 Guidance
Raised. Merit lifted the bottom of the range by $4 million and trimmed the top by $1 million, moving the middle up $1.5 million to 8.1% growth (7.0–7.5% in constant currency). By our math, that leaves $421.5 million or 7.0% growth for the fourth quarter. It is the third raise this year—+$3.0M, +$14.0M, +$1.5M—and if the four-quarter 2.0% beat pattern holds, full-year sales would reach $1.647 billion, by our math.
Raised. The middle of the range rose $0.05 to $4.35, or 13.6% growth from last year, passing through the third-quarter beat and $0.02 less convertible-note dilution. By our math, the plan leaves $1.10 for the fourth quarter, up 5.8% from $1.04 a year ago and down from 21.7% growth in the third quarter. Earlier raises were $0.00 and +$0.22.
❓ Key Questions
How much did OneMark contribute in its first commercial quarter?
Total acquired revenue in the organic reconciliation table was $2.63 million, below the $2.8–3.8 million management projected for the third quarter. Investors need to know if View Point's OneMark system faced launch delays or slower hospital purchasing.
Why did gross margin excluding one-offs fall 0.8 percentage points?
Gross margin excluding one-offs dropped to 52.8% from 53.6% a year ago and 55.8% last quarter (which included a tariff refund). Management did not state in the release how much came from tariffs versus lower-margin OEM mix.
Why did inventories grow another $17 million in the third quarter?
Management expected first-half inventory builds for product launches and factory transfers to taper off, yet inventories reached $391.0 million and held back nine-month free cash flow to $129.5 million against a $200 million full-year target.
Why did Procedural Solutions revenue drop 16% from a year ago?
Foundational Procedural Solutions fell 15.9% to $27.2 million, worse than the 11.9% decline over the first nine months. Investors need to know how much of that drop was the DualCap divestiture versus lost tray business.